en · de · es · fr · pt
melanotan-2-notes.peptides6823.com › Wiki › Melanotan-2 Identity And Receptor Pharmacology — Explained

Melanotan-2 Identity And Receptor Pharmacology — Explained

By Editorial Desk · published 2025-11-19 · last reviewed 2025-12-19 · Wiki

Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Background from the literature

== Daptomycin resistance == Daptomycin resistance is still uncommon, but has been increasingly reported in GRE, starting in Korea in 2005, in Europe in 2010, in Taiwan 2011, and in the United States, where nine cases have been reported from 2007 to 2011. Daptomycin resistance emerged in five of the six cases while they were treated. The mechanism of resistance is unknown. A four-million year-old strain of Paenibacillus isolated from soil samples in Lechuguilla Cave was found to be naturally resistant to daptomycin.It has been suggested that co-administration of daptomycin with at least another active antibiotic might help prevent the emergence of resistance and increase the bactericidal effect. Data from in vitro and in vivo studies suggest that a tailored approach should be used taking into account both the causative agent and the site of infection.

==== In everyday life ==== The principal effect on BV in everyday life is the organism's current diet, although many other factors such as age, health, weight, sex, etc. all have an effect. In short any condition which can affect the organism's metabolism will vary the BV of a protein source. In particular, whilst on a high protein diet the BV of all foods consumed is reduced — the limiting rate at which the amino acids may be incorporated into the body is not the availability of amino acids but the rate of protein synthesis possible in cells. This is a major point of criticism of BV as a test; the test diet is artificially protein rich and may have unusual effects.

Kimon Georgiev married Veselina Rodeva from the prominent Rodeva family of Burgas, they had two daughters - Maria (1928–1986) and Kornelia (b. 1931). Maria became an agronomist and university lecturer and was married to the Fatherland Front functionary Ginyo Ganev. Kimon Georgiev during his non-political time, he would engage in public work, in which he supported himself from his wife's large vineyards. This brought him a considerable income, in which he earned about 4-5 million leva from the production of wine and grapes in the 1940s.

Relaxin/insulin-like family peptide receptor 2, also known as RXFP2, is a human G-protein coupled receptor. The receptors for glycoprotein hormones such as follicle-stimulating hormone (FSH; see MIM 136530) and thyroid-stimulating hormone (TSH; see MIM 188540) are G protein-coupled, 7-transmembrane receptors (GPCRs) with large N-terminal extracellular domains. Leucine-rich repeat (LRR)-containing GPCRs (LGRs) form a subgroup of the GPCR superfamily. [supplied by OMIM].

Electrodes and Structural Transformations: During charge and discharge cycles, the materials in the anodes and cathodes undergo local structural transformations. These changes can be monitored using NMR by analyzing the signal's line shape, line intensity, and chemical shift. These transformations are often not captured by X-ray diffraction techniques (providing long-range information), making NMR indispensable for understanding the underlying mechanisms of energy storage. Metal Dendrite Formation: One of the challenges in lithium and sodium-based batteries is the formation of metal dendrites, which can lead to short circuits and catastrophic battery failure. In Situ NMR allows researchers to observe the formation of lithium or sodium dendrites in real time during battery cycling. Varying the cycling rates can also quantify the effect on dendrite formation, aiding in the development of strategies to suppress dendrite growth and reduce the risk of short circuits. Solid Electrolytes and Interfaces: Solid electrolytes, a key focus of next-generation battery research, often suffer from limited ion diffusion rates. NMR techniques can measure diffusivity in solid electrolytes, helping researchers understand how to enhance ion conductivity. Furthermore, NMR is used to study the Solid Electrolyte Interface (SEI), a layer that forms on the electrode surface and thus influences battery stability. Solid-state NMR (ssNMR) is particularly valuable for characterizing the composition and ion dynamics within the SEI layer due to its nondestructive testing capabilities.

Sources: en.wikipedia.org

Further detail

== Dietary sources == Animal fats are complex mixtures of triglycerides, with lesser amounts of both the phospholipids and cholesterol molecules from which all animal (and human) cell membranes are constructed. Since all animal cells manufacture cholesterol, all animal-based foods contain cholesterol in varying amounts. Major dietary sources of cholesterol include red meat, egg yolks and whole eggs, liver, kidney, giblets, fish oil, shellfish, and butter. Human breast milk also contains significant quantities of cholesterol. Plant cells synthesize cholesterol as a precursor for other compounds, such as phytosterols and steroidal glycoalkaloids, with cholesterol remaining in plant foods only in minor amounts or absent. Some plant foods, such as avocado, flax seeds and peanuts, contain phytosterols, which compete with cholesterol for absorption in the intestines and reduce the absorption of both dietary and bile cholesterol. A typical diet contributes in the order of 0.2 grams of phytosterols, not enough to have a significant impact on blocking cholesterol absorption. The intake of phytosterols can be supplemented through the use of phytosterol-containing functional foods or dietary supplements that are recognized as having potential to reduce levels of LDL-cholesterol.

In April 2026, Moore signed Kanaiayah's Law, which establishes a guardianship assistance program and state foster youth ombudsman. In May 2026, Moore signed into law the No Kings Act, which allows Maryland residents to sue federal officials who violate another's constitutional rights under color of law.

== Community engagement == UPMC has committed to several community projects, most notably pledging $100 million to the Pittsburgh Promise, a scholarship program to help students graduating from the Pittsburgh Public Schools pursue post-secondary education, and $525 million for construction of a new Children's Hospital. In fiscal year 2012, UPMC donated a combined $622 million in charitable community benefits. This included $96 million in community health programs and charitable donations to help stage more than 3,000 community health improvement programs, $288 million in support for research and education, and $238 million for charity care and unreimbursed health care, not including an additional $146 million to cover Medicare reimbursement shortfalls. Despite its 60% market share, UPMC accounted for 78% of the care in Allegheny County's low income communities and 88% of the care for children living in poverty. UPMC contributed $887 million, or more than 15 percent of its net patient revenue, to community services in Fiscal Year 2013, and provides more care to the most underserved areas than any other health care institution in the region.

=== Wound healing in animals === A series of animal experiments established pronounced wound healing activity of GHK-Cu. In the dermal wounds of rabbits GHK-Cu facilitated wound healing, causing better wound contraction, faster development of granular tissue and improved angiogenesis. It also elevated the level of antioxidant enzymes. GHK-Cu has been found to induce a systemic enhancement of healing in rats, mice, and pigs; that is, the GHK-Cu peptide injected in one area of the body (such as the thigh muscles) improved healing at distant body areas (such as the ears). These treatments strongly increased healing parameters such as collagen production, angiogenesis, and wound closure in both wound chambers and full thickness wounds. In one study, full‐thickness wounds of 6 millimeters in diameter were created in an ischemic skin flap on the backs of rats, and for 13 days the wound sites were then treated daily with topical GHK-Cu or topical hydroxypropyl methylcellulose vehicle, or given no treatment. At the end of the study, the wound size had decreased by 64.5% in the GHK group; by 45.6% in the vehicle-treated group; and by 28.2% in the control group. The difference between the GHK group's wounds and those of the control group was significant, and was accompanied by significantly lower levels of tumor necrosis factor alpha and elastin-degrading matrix metalloproteinases. Biotinylated GHK-Cu was incorporated into a collagen membrane, which was used as a wound dressing.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network